in this issue
Pharma/fine chemicals roundup—2 April
8:16 AM MDT | April 2, 2013 | By DEEPTI RAMESH
Ferro sells pharma business
Ferro has completed the sale of its pharmaceuticals business, Pfanstiehl Laboratories, to private equity firm Med Opportunity Partners (Greenwich, CT). Ferro will receive $16.9 million cash and an incentive payment of up to $8 million, payable over 2 years based on the unit's earnings performance. Ferro says it has also retained certain tax benefits with an estimated value of approximately $5 million. Ferro’s pharmaceuticals business posted sales of $24 million and generated a segment income of $2.4 million in 2012.
Daiichi Sankyo integrates pharma ingredient manufacturing plants at Odawara
Pharmaceutical company Daiichi Sankyo (Tokyo) says it completed the previously announced integration of the manufacturing plants of its Daiichi Sankyo Propharma (DSPP; Tokyo) and Daiichi Sankyo Chemical Pharma (DSCP; Hiratsuka, Japan) subsidiaries at Odawara, Japan, on 1 April.
The DSPP Odawara plant, which started operating in 1979, produces active pharmaceutical ingredients (APIs) and employs about 140 people. The DSCP Odawara plant became operational in 1963. It produces intermediates for pharmaceuticals and employs about 120 people. The DSPP Odawara plant has been absorbed into DSCP, which will act as the succeeding company. Postintegration, the DSCP Odawara site employs about 250 people and produces APIs and intermediates for pharmaceuticals.
Evonik Birmingham Laboratories gets cGMP certification
Evonik Industries says that its Birmingham Laboratories (Birmingham, AL) site received cGMP certification from the Medicines and Healthcare products Regulatory Agency (MHRA; London). The site became a part of Evonik through the 2011 acquisition of SurModics Pharmaceuticals. Prior to the Evonik acquisition and since its commissioning in 2010, the site had been used for manufacturing clinical lots for many clients. It now serves as the Evonik hub for parenteral drug delivery and commercial drug product manufacture for nonproprietary or customer-proprietary formulations. Birmingham Laboratories focuses primarily on the production of aseptic and terminally sterilized complex dosage forms including microspheres, drug-loaded implants, and liposomes.
Birmingham Laboratories is also one of two Evonik sites worldwide that manufacture cGMP biodegradable polymers based on poly(lactic-co-glycolic acid), a critical raw material for advanced drug delivery products and bioresorbable medical devices, the company says.
Sanofi builds new manufacturing facility in Vietnam
Sanofi (Paris) says it has begun construction on a new manufacturing facility in the Saigon Hi-tech Park, at Ho Chi Minh City. The investment in the new plant will amount to $75 million and will constitute Sanofi’s largest investment in Vietnam to date. The facility will produce pharmaceuticals and consumer health-care products. The plant is scheduled to be fully operational by the end of 2015, and it will expand Sanofi’s manufacturing capacity in Vietnam to meet the fast growing demand of the Vietnamese pharmaceutical market and serve as an export platform to Asean countries, Sanofi says.
Beyond IHS Chemical Week:
Bulk drug makers eye Japanese generic market
from Business Standard, India
Japan has emerged as a focus market for Indian bulk drug makers. Active pharmaceutical ingredient (API) makers like Ahmadabad-based Dishman Pharmaceuticals, Hyderabad-based Suven Life Sciences, and Chandigarh-based Ind-Swift Laboratories are all upbeat on the Japanese market.
Drug Controller General of India to inspect bulk drug plants exporting to EU
from The Economic Times, India
The Drug Controller General of India is readying a plan to check if domestic bulk drug facilities that export to the European Union comply with World Health Organization–prescribed norms, according to an official. As per the proposed plan, the zonal offices of the drug regulator will inspect the manufacturing practices of active pharmaceutical ingredient plants across the country for compliance and forward the details to the EU drug regulator.